Despite the unprecedented challenges of the past year, we continued to meet the needs of patients and deliver positive results both for shareholders and the communities we serve. Read our 2021 Annual Integrated Report to learn more: https://bit.ly/3haa9Yo
NEW YORK, June 7, 2021 /3BL Media/ —Representing $800 billion in market capitalization, nine CEOs from the biopharma sector will speak virtually about their company’s long-term approach to sustainable business, June 7-8, 2021.
Takeda’s flagship Access to Medicines initiative, the Blueprint for Innovative Healthcare Access program, works with a consortium of public and private partners sharing resources and responsibility, each bringing specific strengths and expertise to address rising Non-Communicable Diseases (NCDs) challenges in underserved communities. Meet the people who are living and breathing the Blueprint in the second episode focusing on the importance of screening of NCDs of a 5-part series of our pilot program in Meru County, Kenya.
Blueprint for Access to Innovative Healthcare is Takeda’s flagship Access to Medicines initiative to accelerate global progress in the prevention and treatment of Non-Communicable Diseases (NCDs). Watch the first episode of a 5-part series of our pilot program in Meru County, on awareness and prevention of NCDs and meet the people who are living and breathing the Blueprint.
Diversity, Equity and Inclusion is an integral part of our corporate philosophy. We create an equitable environment where diversity is welcomed and everyone can bring their true self to the workplace. Listen to our team in Lessines, Belgium, what it means to them.
Innovating to protect the planet is sustainability in action. Our manufacturing site in Lessines, Belgium, is pioneering wastewater circularity in the pharma industry. The facility installed a water treatment system which will be used to supplement fresh water for the drug production process, reducing up to 90 percent of freshwater consumption. This equals an annual water consumption for approximately 18,000 Belgian citizens. As a secondary benefit, this innovative process will also reduce chemicals needed for water treatment. #climatechange #worldwaterday Watch the video to learn more.
The Takeda Executive Team has joined with our employees around the globe to pledge to make the world more gender equal. Our leaders are committed to ensuring women throughout Takeda and beyond are able to grow and advance. Because only by harnessing the talents of every team member can we make a positive difference to patients, people and the planet. What do you #ChooseToChallenge?
Like so many, I am cautiously optimistic that finally, with the availability of at least two COVID-19 vaccines, there is a light at the end of the tunnel. The collaboration we saw within the biopharmaceutical industry and with US agencies such as the FDA and NIH to develop and authorize multiple treatments and two vaccines in just one year has demonstrated the potential and marvel of medical science. Under the new administration, I am confident that manufacturers and public officials will work together with urgency to get the vaccine to every citizen who wishes to receive it.
Achievement Represents a Significant Milestone in the Company’s Commitment to Become Carbon Zero in its Operations by 2040
OSAKA, Japan, January 27, 2021 /3BL Media/ – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it achieved carbon neutrality in its value chain for its fiscal year 2019. This achievement was delivered by a continued focus on internal energy conservation measures, procurement of green energy, and investment in renewable energy certificates and high-quality, verified carbon offsets.